Lung cancer outcomes significantly improved with immunotherapy-based treatment given before and after surgery
A regimen of pre-surgical immunotherapy and chemotherapy followed by post-surgical immunotherapy significantly improved event-free survival (EFS) and pathologic complete response (pCR) rates compared to chemotherapy alone for patients with operable non-small cell lung cancer (NSCLC), according to Phase III trial results presented today by researchers from The University of Texas MD Anderson Cancer Center at the American Association for...
MD Anderson and Generate:Biomedicines enter co-development and commercialization agreement to accelerate novel protein therapeutics for oncology using generative AI
The University of Texas MD Anderson Cancer Center and Generate:Biomedicines today announced a strategic collaboration to jointly discover...
AACR: Mutations in three key genes associated with poor outcomes in lung cancer patients treated with KRAS G12C inhibitors
ABSTRACT: 3431
A new study led by researchers at The University of Texas MD Anderson Cancer Center discovered that co-occurring mutations...
MD Anderson applauds NCI’s National Cancer Plan
The University of Texas MD Anderson Cancer Center applauds the National Cancer Institute’s (NCI) National Cancer Plan and its framework for collaboration to bring the nation together in a focused effort to end suffering from cancer.
“Scientific breakthroughs are essential for driving progress in health and medicine, but collaboration is equally important to translate those discoveries into meaningful progress against cancer...
